Vivimed Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE526G01021
  • NSEID: VIVIMEDLAB
  • BSEID: 532660
INR
6.53
0.23 (3.65%)
BSENSE

May 14

BSE+NSE Vol: 1.24 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.24 lacs (11.13%) Volume

Shareholding (Mar 2026)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.57%

When is the next results date for Vivimed Labs Ltd?

10-Mar-2026

The next results date for Vivimed Labs Ltd is 13 March 2026.

The next results date for Vivimed Labs Ltd is scheduled for 13 March 2026.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

12-May-2026

Why is Vivimed Labs Ltd falling/rising?

13-May-2026

As of 13-May, Vivimed Labs Ltd's stock price is at 6.30, reflecting a significant decline of 64.27% year-to-date and a bearish trend, trading below all key moving averages despite increased investor participation. The stock has consistently underperformed compared to the Sensex, with a 10% drop over the last four days.

As of 13-May, Vivimed Labs Ltd's stock price is falling, currently at 6.30, which reflects a decrease of 0.21 or 3.23%. The stock has been underperforming significantly, with a decline of 5.97% over the past week and 10.76% over the past month, compared to the Sensex, which has fallen only 4.30% and 2.91%, respectively. Year-to-date, the stock has plummeted by 64.27%, while the Sensex has only decreased by 12.45%. <BR><BR>Additionally, the stock has been on a consecutive decline for the last four days, resulting in a total drop of 10% during this period. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Although there has been a notable increase in investor participation, with a delivery volume rise of 297.04% against the 5-day average, this has not translated into a positive price movement. Overall, the combination of significant declines in stock performance relative to the benchmark and the sustained downward trend contributes to the current falling price of Vivimed Labs Ltd.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With HIgh Debt (Debt-Equity Ratio at 9.51 times)- the company has a Weak Long Term Fundamental Strength

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.02 times
  • The company has reported losses. Due to this company has reported negative ROE
2

Flat results in Dec 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 52 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

35

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.51

stock-summary
Return on Equity

-833.41%

stock-summary
Price to Book

1.33

Revenue and Profits:
Net Sales:
16 Cr
(Quarterly Results - Dec 2025)
Net Profit:
-17 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.11%
0%
-12.11%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
1.71%
0%
1.71%
4 Years
-52.68%
0%
-52.68%
5 Years
-80.09%
0%
-80.09%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Vivimed Labs Gains 1.78%: Technical Shift and Upper Circuit Spark Interest

Announcements stock-summary

Corporate Insolvency Resolution Process (CIRP)-Public Announcement

23-Apr-2026 | Source : BSE

Form A - Public Announcement

Admission To CIRP

17-Apr-2026 | Source : BSE

ADMISSION TO CIRP

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

08-Apr-2026 | Source : BSE

certificate under reg 74(5)

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

stock-summary
SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-53.40%
EBIT Growth (5y)
-421.22%
EBIT to Interest (avg)
-1.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
9.51
Sales to Capital Employed (avg)
0.80
Tax Ratio
0.64%
Dividend Payout Ratio
0
Pledged Shares
15.18%
Institutional Holding
1.76%
ROCE (avg)
-0.76%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
35
Price to Book Value
1.33
EV to EBIT
-13.35
EV to EBITDA
-38.30
EV to Capital Employed
1.03
EV to Sales
3.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-71.39%
ROE (Latest)
-833.41%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

15.1806

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Varalwar Sandeep (2.81%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

68.75%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.63",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.22",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.94",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-16.57",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.27",
          "val2": "187.10",
          "chgp": "-37.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.05",
          "val2": "-187.30",
          "chgp": "93.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.95",
          "val2": "35.90",
          "chgp": "-91.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.96",
          "val2": "-328.53",
          "chgp": "90.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11.22%",
          "val2": "-100.11%",
          "chgp": "88.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Change(%)
Net Sales
11.63
NA
NA
Operating Profit (PBDIT) excl Other Income
-11.22
NA
NA
Interest
0.94
NA
NA
Exceptional Items
0.00
NA
NA
Standalone Net Profit
-16.57
NA
NA
Operating Profit Margin (Excl OI)
-96.47%
NA%
NA
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Half Yearly Results Snapshot (Consolidated) - Sep'22stock-summary

Sep'22
Sep'21
Change(%)
Net Sales
94.33
119.63
-21.15%
Operating Profit (PBDIT) excl Other Income
-17.88
0.31
-5,867.74%
Interest
18.17
18.12
0.28%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-44.23
-25.63
-72.57%
Operating Profit Margin (Excl OI)
-18.95%
0.26%
-19.21%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

Nine Monthly Results Snapshot (Consolidated) - Dec'22stock-summary

Dec'22
Dec'21
Change(%)
Net Sales
150.07
176.15
-14.81%
Operating Profit (PBDIT) excl Other Income
-23.01
-6.98
-229.66%
Interest
27.39
29.70
-7.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-62.54
-49.31
-26.83%
Operating Profit Margin (Excl OI)
-15.33%
-3.96%
-11.37%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'23
Change(%)
Net Sales
116.27
187.10
-37.86%
Operating Profit (PBDIT) excl Other Income
-13.05
-187.30
93.03%
Interest
2.95
35.90
-91.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-31.96
-328.53
90.27%
Operating Profit Margin (Excl OI)
-11.22%
-100.11%
88.89%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023

stock-summaryCompany CV
About Vivimed Labs Ltd stock-summary
stock-summary
Vivimed Labs Ltd
Micro Cap
Pharmaceuticals & Drugs
Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.
Company Coordinates stock-summary
Company Details
Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403
stock-summary
Tel: 91-8482-232045
stock-summary
yugandhar.kopparthi@vivimeslabs.com
Registrar Details
Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad